U54 DK126126/DK/NIDDK NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2020	4
2021	6
2022	9
2023	10
2024	2

1

PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression.

Lakhia R, Ramalingam H, Chang CM, Cobo-Stark P, Biggers L, Flaten A, Alvarez J, Valencia T, Wallace DP, Lee EC, Patel V. Lakhia R, et al. Nat Commun. 2022 Aug 15;13(1):4765. doi: 10.1038/s41467-022-32543-2. Nat Commun. 2022. PMID: 35965273 Free PMC article.

2

A methionine-Mettl3-N⁶-methyladenosine axis promotes polycystic kidney disease.

Ramalingam H, Kashyap S, Cobo-Stark P, Flaten A, Chang CM, Hajarnis S, Hein KZ, Lika J, Warner GM, Espindola-Netto JM, Kumar A, Kanchwala M, Xing C, Chini EN, Patel V. Ramalingam H, et al. Cell Metab. 2021 Jun 1;33(6):1234-1247.e7. doi: 10.1016/j.cmet.2021.03.024. Epub 2021 Apr 13. Cell Metab. 2021. PMID: 33852874 Free PMC article.

3

Biomarkers in Polycystic Kidney Disease: Are We There?

Yu ASL, Landsittel DP. Yu ASL, et al. Adv Kidney Dis Health. 2023 May;30(3):285-293. doi: 10.1053/j.akdh.2022.12.009. Adv Kidney Dis Health. 2023. PMID: 37088529 Review.

4

The GPCR properties of polycystin-1- A new paradigm.

Maser RL, Calvet JP, Parnell SC. Maser RL, et al. Front Mol Biosci. 2022 Nov 4;9:1035507. doi: 10.3389/fmolb.2022.1035507. eCollection 2022. Front Mol Biosci. 2022. PMID: 36406261 Free PMC article. Review.

5

Polycystin-1 Interacting Protein-1 (CU062) Interacts with the Ectodomain of Polycystin-1 (PC1).

Lea WA, Winklhofer T, Zelenchuk L, Sharma M, Rossol-Allison J, Fields TA, Reif G, Calvet JP, Bakeberg JL, Wallace DP, Ward CJ. Lea WA, et al. Cells. 2023 Aug 29;12(17):2166. doi: 10.3390/cells12172166. Cells. 2023. PMID: 37681898 Free PMC article.

6

CaMK4 overexpression in polycystic kidney disease promotes mTOR-mediated cell proliferation.

Zhang Y, Daniel EA, Metcalf J, Dai Y, Reif GA, Wallace DP. Zhang Y, et al. J Mol Cell Biol. 2022 Sep 27;14(7):mjac050. doi: 10.1093/jmcb/mjac050. J Mol Cell Biol. 2022. PMID: 36002021 Free PMC article.

7

The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.

Jamadar A, Suma SM, Mathew S, Fields TA, Wallace DP, Calvet JP, Rao R. Jamadar A, et al. Cell Death Dis. 2021 Oct 14;12(10):947. doi: 10.1038/s41419-021-04248-9. Cell Death Dis. 2021. PMID: 34650051 Free PMC article.

8

Kidney stone formation in a novel murine model of polycystic kidney disease.

Riddle HAL, Zhang S, Qian F, Williams JC Jr, Stubbs JR, Rowe PSN, Parnell SC. Riddle HAL, et al. Am J Physiol Renal Physiol. 2022 Jul 1;323(1):F59-F68. doi: 10.1152/ajprenal.00165.2021. Epub 2022 Mar 28. Am J Physiol Renal Physiol. 2022. PMID: 35343849 Free PMC article.

9

The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease.

Sundar SV, Zhou JX, Magenheimer BS, Reif GA, Wallace DP, Georg GI, Jakkaraj SR, Tash JS, Yu ASL, Li X, Calvet JP. Sundar SV, et al. Am J Physiol Renal Physiol. 2022 Oct 1;323(4):F492-F506. doi: 10.1152/ajprenal.00095.2022. Epub 2022 Aug 18. Am J Physiol Renal Physiol. 2022. PMID: 35979967 Free PMC article.

10

Metabolomic profiling to identify early urinary biomarkers and metabolic pathway alterations in autosomal dominant polycystic kidney disease.

Houske EA, Glimm MG, Bergstrom AR, Slipher SK, Welhaven HD, Greenwood MC, Linse GM, June RK, Yu ASL, Wallace DP, Hahn AK. Houske EA, et al. Am J Physiol Renal Physiol. 2023 Jun 1;324(6):F590-F602. doi: 10.1152/ajprenal.00301.2022. Epub 2023 May 4. Am J Physiol Renal Physiol. 2023. PMID: 37141147

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

30 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year